InMed Pharmaceuticals (INM) Common Equity (2019 - 2026)

InMed Pharmaceuticals' Common Equity history runs 8 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• On a quarterly basis, Common Equity fell 1.85% year-over-year to $6.9 million in Q1 2026; TTM through Mar 2026 was $6.9 million, a 1.85% decrease from a year earlier, with the FY2025 full-year figure at $13.4 million, up 45.93% from the prior year.
• Common Equity declined to $6.9 million in Q1 2026 per INM's latest filing, from $9.6 million in the prior quarter.
• Across five years, Common Equity topped out at $14.3 million in Q4 2022 and bottomed at -$9.6 million in Q3 2023.
• The 5-year median for Common Equity is $10.9 million (2022), against an average of $9.2 million.
• Across the five-year window, Common Equity sank 187.01% in 2023 and jumped 187.65% in 2024, its largest moves.
• Year by year, Common Equity stood at $14.3 million in 2022, then fell by 10.9% to $12.8 million in 2023, then sank by 51.6% to $6.2 million in 2024, then soared by 55.09% to $9.6 million in 2025, then slipped by 28.12% to $6.9 million in 2026.
• Per Business Quant, the three latest INM Common Equity figures stand at $6.9 million (Q1 2026), $9.6 million (Q4 2025), and $11.6 million (Q3 2025).